As of the latest Form 4 filed Jun 17, 2026.
What Acumen Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 19 most recent filings for ABOS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | 2026-06-17 | Porter Derrell Director | SSale | −13.0K | $2.33 | $30.3K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-17 | Porter Derrell, Director | MExercise | +13.0K | $1.07 | $14.0K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-16 | Porter Derrell, Director | SSale | −12.8K | $2.33 | $29.8K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Porter Derrell, Director | SSale | −6.46K | $2.35 | $15.1K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Porter Derrell, Director | MExercise | +6.46K | $1.07 | $6.91K | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-09 | Fountain Nathan B Director | SSale | −6.40K | $2.23 | $14.3K | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Fountain Nathan B Director | AAward | +35.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Drapkin Kimberlee C Director | AAward | +35.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Stalfort John A III Director | AAward | +35.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Porter Derrell Director | AAward | +35.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Ives Jeffrey L. Director | AAward | +35.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Golumbeski George Director | AAward | +35.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Stoppel Laura Director | AAward | +35.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | RA CAPITAL MANAGEMENT, L.P. Director | AAward | +35.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | RA CAPITAL MANAGEMENT, L.P. Director | AAward | +6.06M | $3.30 | $20.0M | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Meisner Derek M Chief Legal Officer & Corp Sec | SSale | −2.09K | $3.26 | $6.81K | Yes (planned) | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Meisner Derek M, Chief Legal Officer & Corp Sec | MExercise | +2.09K | $1.85 | $3.87K | Yes (planned) | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Meisner Derek M Chief Legal Officer & Corp Sec | SSale | −9.41K | $3.01 | $28.3K | Yes (planned) | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Meisner Derek M, Chief Legal Officer & Corp Sec | MExercise | +9.41K | $1.85 | $17.4K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ABOS’s full analysis or the market-wide insider trading feed. The tabs above jump to ABOS’s other SEC data.
Source: SEC Form 4 filings for ABOS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.